Cargando…

The Alterations of Gut Microbiome and Lipid Metabolism in Patients with Spinal Muscular Atrophy

INTRODUCTION: Spinal muscular atrophy (SMA) can cause multiple system dysfunction, especially lipid metabolic disorders, for which management strategies are currently lacking. Microbes are related to metabolism and the pathogenesis of neurological diseases. This study aimed to preliminarily explore...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Yijie, Cui, Yiqin, Jin, Jianing, Huang, Siyi, Wei, Jia, Yao, Mei, Zhou, Dongming, Mao, Shanshan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134726/
https://www.ncbi.nlm.nih.gov/pubmed/37103747
http://dx.doi.org/10.1007/s40120-023-00477-6
_version_ 1785031820295798784
author Feng, Yijie
Cui, Yiqin
Jin, Jianing
Huang, Siyi
Wei, Jia
Yao, Mei
Zhou, Dongming
Mao, Shanshan
author_facet Feng, Yijie
Cui, Yiqin
Jin, Jianing
Huang, Siyi
Wei, Jia
Yao, Mei
Zhou, Dongming
Mao, Shanshan
author_sort Feng, Yijie
collection PubMed
description INTRODUCTION: Spinal muscular atrophy (SMA) can cause multiple system dysfunction, especially lipid metabolic disorders, for which management strategies are currently lacking. Microbes are related to metabolism and the pathogenesis of neurological diseases. This study aimed to preliminarily explore the alterations in the gut microbiota in SMA and the potential relationship between altered microbiota and lipid metabolic disorders. METHODS: Fifteen patients with SMA and 17 gender- and age-matched healthy controls were enrolled in the study. Feces and fasting plasma samples were collected. 16S ribosomal RNA sequencing and nontargeted metabolomics analysis were performed to explore the correlation between microbiota and differential lipid metabolites. RESULTS: No significant difference was found in microbial diversity (α- and β-diversity) between the SMA and control groups, with both groups having a relatively similar community structure. However, compared to the control group, the SMA group showed an increased relative abundance of the genera Ruminiclostridium, Gordonibacter, Enorma, Lawsonella, Frisingicoccus, and Anaerofilum and a decreased abundance of the genera Catabacter, Howardella, Marine_Methylotrophic_Group_3, and Lachnospiraceae_AC2044_group. The concurrent metabolomic analysis showed that the SMA group had 56 different kinds of lipid metabolite levels than did the control group. Additionally, the Spearman correlation suggested a correlation between the altered differential lipid metabolites and the above-mentioned altered microbiota. CONCLUSIONS: The gut microbiome and lipid metabolites differed between the patients with SMA and the control subjects. The altered microbiota may be related with the lipid metabolic disorders in SMA. However, further study is necessary to clarify the mechanism of lipid metabolic disorders and develop management strategies to improve the related complications in SMA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40120-023-00477-6.
format Online
Article
Text
id pubmed-10134726
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-101347262023-04-28 The Alterations of Gut Microbiome and Lipid Metabolism in Patients with Spinal Muscular Atrophy Feng, Yijie Cui, Yiqin Jin, Jianing Huang, Siyi Wei, Jia Yao, Mei Zhou, Dongming Mao, Shanshan Neurol Ther Original Research INTRODUCTION: Spinal muscular atrophy (SMA) can cause multiple system dysfunction, especially lipid metabolic disorders, for which management strategies are currently lacking. Microbes are related to metabolism and the pathogenesis of neurological diseases. This study aimed to preliminarily explore the alterations in the gut microbiota in SMA and the potential relationship between altered microbiota and lipid metabolic disorders. METHODS: Fifteen patients with SMA and 17 gender- and age-matched healthy controls were enrolled in the study. Feces and fasting plasma samples were collected. 16S ribosomal RNA sequencing and nontargeted metabolomics analysis were performed to explore the correlation between microbiota and differential lipid metabolites. RESULTS: No significant difference was found in microbial diversity (α- and β-diversity) between the SMA and control groups, with both groups having a relatively similar community structure. However, compared to the control group, the SMA group showed an increased relative abundance of the genera Ruminiclostridium, Gordonibacter, Enorma, Lawsonella, Frisingicoccus, and Anaerofilum and a decreased abundance of the genera Catabacter, Howardella, Marine_Methylotrophic_Group_3, and Lachnospiraceae_AC2044_group. The concurrent metabolomic analysis showed that the SMA group had 56 different kinds of lipid metabolite levels than did the control group. Additionally, the Spearman correlation suggested a correlation between the altered differential lipid metabolites and the above-mentioned altered microbiota. CONCLUSIONS: The gut microbiome and lipid metabolites differed between the patients with SMA and the control subjects. The altered microbiota may be related with the lipid metabolic disorders in SMA. However, further study is necessary to clarify the mechanism of lipid metabolic disorders and develop management strategies to improve the related complications in SMA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40120-023-00477-6. Springer Healthcare 2023-04-27 /pmc/articles/PMC10134726/ /pubmed/37103747 http://dx.doi.org/10.1007/s40120-023-00477-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Feng, Yijie
Cui, Yiqin
Jin, Jianing
Huang, Siyi
Wei, Jia
Yao, Mei
Zhou, Dongming
Mao, Shanshan
The Alterations of Gut Microbiome and Lipid Metabolism in Patients with Spinal Muscular Atrophy
title The Alterations of Gut Microbiome and Lipid Metabolism in Patients with Spinal Muscular Atrophy
title_full The Alterations of Gut Microbiome and Lipid Metabolism in Patients with Spinal Muscular Atrophy
title_fullStr The Alterations of Gut Microbiome and Lipid Metabolism in Patients with Spinal Muscular Atrophy
title_full_unstemmed The Alterations of Gut Microbiome and Lipid Metabolism in Patients with Spinal Muscular Atrophy
title_short The Alterations of Gut Microbiome and Lipid Metabolism in Patients with Spinal Muscular Atrophy
title_sort alterations of gut microbiome and lipid metabolism in patients with spinal muscular atrophy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134726/
https://www.ncbi.nlm.nih.gov/pubmed/37103747
http://dx.doi.org/10.1007/s40120-023-00477-6
work_keys_str_mv AT fengyijie thealterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy
AT cuiyiqin thealterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy
AT jinjianing thealterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy
AT huangsiyi thealterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy
AT weijia thealterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy
AT yaomei thealterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy
AT zhoudongming thealterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy
AT maoshanshan thealterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy
AT fengyijie alterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy
AT cuiyiqin alterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy
AT jinjianing alterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy
AT huangsiyi alterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy
AT weijia alterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy
AT yaomei alterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy
AT zhoudongming alterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy
AT maoshanshan alterationsofgutmicrobiomeandlipidmetabolisminpatientswithspinalmuscularatrophy